Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (prostatic glandular cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: capromab | 0.81 |
| trials ClinicalTrials.gov | 8 Parkinson's trials, 3 stopped | 0.70 |
| literature PubMed | 1 Parkinson's papers of 419 | 0.91 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 5818
Sealed predictions
- KLK3 in dopamine neurons, braak+0.01 (p 0.982) → -0.31 (p 0.416)receipt 5825
Swarm cases
receipt 5825: KLK3 in dopamine neurons, braak
- power
- full sample -0.22 (p 0.379, n 18), 95% CI -0.62 to +0.27. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.24 (p 0.332, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.27 (p 0.285, n 18). could be the mix.
- skeptic
- leave-one-out range -0.35 to -0.13, sign flips 0; without severely affected donors -0.22 (p 0.379, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for KLK3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts